Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study

BACKGROUND: Ribavirin (RBV) is an essential component of most current hepatitis C (HCV) treatment regimens and still standard of care in the combination with pegylated interferon (pegIFN) to treat chronic HCV in resource limited settings. Study results in HIV/HCV-coinfected patients are contradictin...

Descripción completa

Detalles Bibliográficos
Autores principales: Kovari, Helen, Russmann, Stefan, Ledergerber, Bruno, Müller, Daniel, Rotger, Margalida, Velli, Pablo, Cavassini, Matthias, Ambrosioni, Juan, Bregenzer, Andrea, Stöckle, Marcel, Bernasconi, Enos, Rauch, Andri, Speck, Roberto F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517877/
https://www.ncbi.nlm.nih.gov/pubmed/26218843
http://dx.doi.org/10.1371/journal.pone.0133879

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517877/
https://www.ncbi.nlm.nih.gov/pubmed/26218843
http://dx.doi.org/10.1371/journal.pone.0133879

Ejemplares similares